|
|
|
| A comparative study of RECIST1.0 and mRECIST in evaluating TACE treatment response forpatients with hepatocellular carcinomas |
| DING Jie, DAI Xu, SU Hong-ying, MENG Xian-yun, WANG Guan |
| Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China |
|
|
|
|
Abstract Objective: CT was used to compare using the response evaluation cirteria in solid tumor 1.0(RECIST1.0) and modified RECIST(mRECIST) in evaluation the treatment effect of TACE for patients with HCC, so as to choose a more optimal cirteria for evaluating the treatment effect. Methods: Seventy patients diagnosed as HCC had at least 3 chemoembolization procedures, and at 1 week before the procedure; 1 month; 3 months after the procedures had CT or MR examinations respectively. At least two radiologists according to RECIST1.0 and mRECIST criterion to assess the result of TACE therapy. The response rate of the two criterion was evaluated with χ2 test. Results: Use RECIST1.0 to evaluate the therapeutic effect of TACE: CR was 0, PR was 9, SD was 38, PD was 23, response rate was 12.86%. If use mRECIST for evaluation: CR was 12, PR was 15, SD was 22, PD was 21, response rate was 38.57%(χ2 test, P＜0.05), There was significant differences between the two criterion. Conclusion: To use mRECIST criteria in evaluating the response rate of TACE treatment for HCC, emphasis is put on measuring the enhanced viable tumor in the arterial phase by enhanced CT, it can play a decisive role for subsequent treatment planning.
|
|
Received: 25 March 2014
|
|
|
|
|
|
|
|
|
2014, Vol. 25 
